Bitcoin halving
What does that mean?
$2.76T
Total marketcap
$109.05B
Total volume
BTC 49.66%     ETH 15.36%
Dominance

Biogen BIIB Stock

215.63 USD {{ price }} -0.328183% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
31.34B USD
LOW - HIGH [24H]
214 - 217.57 USD
VOLUME [24H]
1.76M USD
{{ volume }}
P/E Ratio
27.02
Earnings per share
7.98 USD

Biogen Price Chart

Biogen BIIB Financial and Trading Overview

Biogen stock price 215.63 USD
Previous Close 299.99 USD
Open 299.77 USD
Bid 0 USD x 900
Ask 0 USD x 900
Day's Range 293.21 - 299.99 USD
52 Week Range 192.11 - 319.76 USD
Volume 1.46M USD
Avg. Volume 968.15K USD
Market Cap 43.11B USD
Beta (5Y Monthly) 0.184507
PE Ratio (TTM) 14.182381
EPS (TTM) 7.98 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 335.04 USD

BIIB Valuation Measures

Enterprise Value 44.67B USD
Trailing P/E 14.182381
Forward P/E 18.138245
PEG Ratio (5 yr expected) 7.77
Price/Sales (ttm) 4.2662263
Price/Book (mrq) 3.1258395
Enterprise Value/Revenue 4.421
Enterprise Value/EBITDA 13.225

Trading Information

Biogen Stock Price History

Beta (5Y Monthly) 0.184507
52-Week Change 47.63%
S&P500 52-Week Change 20.43%
52 Week High 319.76 USD
52 Week Low 192.11 USD
50-Day Moving Average 300.7 USD
200-Day Moving Average 276.94 USD

BIIB Share Statistics

Avg. Volume (3 month) 968.15K USD
Avg. Daily Volume (10-Days) 1.21M USD
Shares Outstanding 144.74M
Float 144.32M
Short Ratio 2.61
% Held by Insiders 0.68%
% Held by Institutions 89.89%
Shares Short 2.53M
Short % of Float 1.96%
Short % of Shares Outstanding 1.75%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 3:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 30.98%
Operating Margin (ttm) 28.60%
Gross Margin 78.35%
EBITDA Margin 33.42%

Management Effectiveness

Return on Assets (ttm) 7.49%
Return on Equity (ttm) 25.03%

Income Statement

Revenue (ttm) 10.1B USD
Revenue Per Share (ttm) 69.87 USD
Quarterly Revenue Growth (yoy) -2.70%
Gross Profit (ttm) 7.9B USD
EBITDA 3.38B USD
Net Income Avi to Common (ttm) 3.13B USD
Diluted EPS (ttm) 21
Quarterly Earnings Growth (yoy) 27.70%

Balance Sheet

Total Cash (mrq) 5.04B USD
Total Cash Per Share (mrq) 34.83 USD
Total Debt (mrq) 6.61B USD
Total Debt/Equity (mrq) 47.94 USD
Current Ratio (mrq) 3.238
Book Value Per Share (mrq) 95.28

Cash Flow Statement

Operating Cash Flow (ttm) 1.68B USD
Levered Free Cash Flow (ttm) 1.67B USD

Profile of Biogen

Country United States
State MA
City Cambridge
Address 225 Binney Street
ZIP 02142
Phone 617 679 2000
Website https://www.biogen.com
Industry Drug Manufacturers-General
Sector(s) Healthcare
Full Time Employees 8725

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Q&A For Biogen Stock

What is a current BIIB stock price?

Biogen BIIB stock price today per share is 215.63 USD.

How to purchase Biogen stock?

You can buy BIIB shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Biogen?

The stock symbol or ticker of Biogen is BIIB.

Which industry does the Biogen company belong to?

The Biogen industry is Drug Manufacturers-General.

How many shares does Biogen have in circulation?

The max supply of Biogen shares is 145.36M.

What is Biogen Price to Earnings Ratio (PE Ratio)?

Biogen PE Ratio is 27.02130300 now.

What was Biogen earnings per share over the trailing 12 months (TTM)?

Biogen EPS is 7.98 USD over the trailing 12 months.

Which sector does the Biogen company belong to?

The Biogen sector is Healthcare.

Biogen BIIB included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16379.46 USD
-0.12
4.79B USD 16347.38 USD 16420.92 USD 4.79B USD
S&P 500 INDEX SPX 5254.35 USD
+0.11
2.4B USD 2.4B USD
S&P 500 (Yahoo.com) GSPC 5254.35 USD
+0.11
2.4B USD 5245.82 USD 5264.85 USD 2.4B USD
S&P 100 SP100 2478.85 USD
<0.01
1.13B USD 2473.99 USD 2483.99 USD 1.13B USD
US100 NDX 18254.69 USD
-0.14
813.09M USD 18231.38 USD 18308.32 USD 813.09M USD
Dow Jones U.S. Biotechnology In DJUSBT 2880.49 USD
<0.01
137.44M USD 2878.66 USD 2887.95 USD 137.44M USD
NASDAQ Biotechnology NBI 4429.97 USD
-0.36
4426.59 USD 4461.88 USD
NASDAQ 100 Pre Market Indicator QMI 18269.05 USD
-0.06
18251.2 USD 18284.7 USD
NASDAQ HealthCare IXHC 1011.84 USD
-0.04
1011.35 USD 1017.55 USD
NASDAQ OMX CRD Global Sustainab QCRD 1595.1 USD
0
Nasdaq US Smart Pharmaceuticals NQSSPH 1486.34 USD
+0.05
1484.78 USD 1491.97 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD
NASDAQ-100 PM Settlement Value XQC 16331.98 USD
+1.13
16331.98 USD 16331.98 USD
NASDAQ 100 Ex Tech Sector NDXX 5413 USD
+0.08
5408.87 USD 5430.18 USD
NASDAQ 100 Notional Net Total R XNDXNNR 21019.32 USD
-0.14
20992.49 USD 21081.21 USD